Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) Return on Assets (2021 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Return on Assets for 5 consecutive years, with 0.61% as the latest value for Q3 2025.

  • Quarterly Return on Assets rose 243.0% to 0.61% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 0.61% through Sep 2025, up 243.0% year-over-year, with the annual reading at 0.51% for FY2024, 51.0% up from the prior year.
  • Return on Assets for Q3 2025 was 0.61% at Inhibikase Therapeutics, down from 0.48% in the prior quarter.
  • The five-year high for Return on Assets was 0.23% in Q3 2021, with the low at 3.04% in Q3 2024.
  • Average Return on Assets over 5 years is 0.82%, with a median of 0.6% recorded in 2022.
  • The sharpest move saw Return on Assets plummeted -204bps in 2024, then soared 243bps in 2025.
  • Over 5 years, Return on Assets stood at 0.33% in 2021, then crashed by -102bps to 0.68% in 2022, then crashed by -83bps to 1.24% in 2023, then skyrocketed by 55bps to 0.56% in 2024, then dropped by -9bps to 0.61% in 2025.
  • According to Business Quant data, Return on Assets over the past three periods came in at 0.61%, 0.48%, and 0.4% for Q3 2025, Q2 2025, and Q1 2025 respectively.